西达苯胺联合R-DHAP方案治疗复发/难治性弥漫大B细胞淋巴瘤的临床疗效

doi:10.3969/j.issn.1671-7171.2024.04.016

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1193 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨西达苯胺联合R-DHAP方案治疗复发/难治性弥漫大B细胞淋巴瘤(DLBCL)的临床疗效。【方法】78例复发/难治性DLBCL患者,随机分为观察组和对照组。对照组采用R-DHAP方案治疗,观察组采用西达苯胺联合R-DHAP方案治疗。比较两组肿瘤患者体力状况(ECOG)评分,临床疗效,血清血管内皮生长因子(VEGF)、β2-微球蛋白(β2-MG)水平,药物不良反应以及无进展生存时间。【结果】治疗3个疗程后,两组ECOG评分较治疗前均降低(P<0.05),且观察组低于对照组(P<0.05);观察组的客观缓解率高于对照组(P<0.05);两组血清VEGF、β2-MG水平均较治疗前降低(P<0.05),且观察组低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。观察组和对照组患者中位无进展生存时间分别为20.60个月和15.18个月,两组比较,差异有统计学意义(P<0.05)。【结论】西达苯胺联合R-DHAP方案治疗复发/难治性DLBCL患者能够改善临床症状,疗效确切,同时可以降低血清VEGF、β2-MG水平,延长患者生存时间,且安全可靠。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王晓伟
	李宁
	刘婷
	王亚琦

关键词 ：淋巴瘤, 大B细胞, 弥漫性/药物疗法, 抗肿瘤联合化疗方案, 治疗结果

Abstract：【Objective】To explore the efficacy of chidamide combined with R-DHAP regimen in the treatment of relapsed/refractory diffuse large B-cell lymphoma(DLBCL). 【Methods】A total of 78 patients with relapsed/refractory DLBCL were selected and randomly divided into the observation group and the control group. The control group was treated with R-DHAP regimen, and the study group was treated with chidamide combined with R-DHAP regimen. The ECOG score, clinical efficacy, serum vascular endothelial growth factor (VEGF), β2-microglobulin (β2-MG) levels, adverse drug, and progression-free survival time reactions were compared between the two groups. 【Results】After 3 courses of treatment, the ECOG scores of both groups were lower (P<0.05), which the study group showed lower than the control group(P<0.05). The objective remission rate of the observation group was higher than that of the control group (P<0.05). After 3 courses of treatment, the levels of serum VEGF and β2-MG in both groups were lower than those before treatment (P<0.05); And the levels of serum VEGF and β2-MG in the observation group were lower than those in the control group (P<0.05). The incidence of adverse reactions in both groups was not statistically significant (P>0.05). The median progression-free survival curves between the observation group and the control group was 20.60 months and 15.18 months, respectively, which was statistically significant difference (P<0.05). 【Conclusion】Chidamide combined with R-DHAP regimen in the treatment of patients with relapsed/refractory DLBCL can improve clinical symptoms and enhance the curative effect.It can reduce the levels of serum VEGF and β2-MG, prolong the survival time of patients, and it is safe and reliable.

Key words： Lymphoma, Large B-Cell, Diffuse/DT Antineoplastic Combined Chemotherapy Protocols Treatment Outcome

收稿日期: 2023-10-20

中图分类号:

R733.41

通讯作者: ^*E-mail:15991629705@163.com

引用本文:

王晓伟, 李宁, 刘婷, 王亚琦. 西达苯胺联合R-DHAP方案治疗复发/难治性弥漫大B细胞淋巴瘤的临床疗效[J]. 医学临床研究, 2024, 41(4): 537-539.
WANG Xiaowei, LI Ning, LIU Ting, et al. Clinical Efficacy and Survival Analysis of Chidamide Combined with R-DHAP Regimen in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma. JOURNAL OF CLINICAL RESEARCH, 2024, 41(4): 537-539.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.04.016 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I4/537

[1] SEHN L H, HERRERA A F, FLOWERS C R, et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma[J].J Clin Oncol,2020, 38(2):155-165.
[2] HARRIS L J, PATEL K, MARTIN M. Novel therapies for relapsed or refractory diffuse large B-cell lymphoma [J].Int J Mol Sci,2020, 21(22):8553-8559.
[3] WITZENS-HARIG M, VIARDOT A. The mTOR inhibitor temsirolimus added to rituximab combined with dexamethasone, cytarabine, and cisplatinum (R-DHAP) for the treatment of patients with relapsed or refractory DLBCL - results from the Phase-Ⅱ STORM trial [J].Hemasphere,2021, 5(10):636-643.
[4] 温晓莲, 赵瑾, 苏丽萍. 西达本胺治疗外周T细胞淋巴瘤的临床效果及安全性[J].肿瘤研究与临床, 2020, 32(9):633.
[5] 张璐, 江晓莉, 张治业, 等. 西达本胺联合化疗方案治疗复发/难治性AITL合并自身免疫性溶血性贫血1例并文献复习[J].临床血液学杂志, 2019, 32(1):55-57.
[6] 李军民, 管忠震, 沈悌, 等. 中国弥漫大B细胞淋巴瘤诊断与治疗指南(2013年版)[J].中华血液学杂志, 2013, 34(9):816-819.
[7] 王树叶, 王晨. 淋巴瘤简明诊疗策略[M]. 北京:人民卫生出版社, 2013:102-103.
[8] 徐应永.疗效评价标准在恶性淋巴瘤临床研究中的应用[J].临床肿瘤学杂志, 2019, 24(3):256-261.
[9] MILLER T P, FISHER B T, GETZ K D, et al. Unintended consequences of evolution of the common terminology criteria for adverse events [J].Pediatr Blood Cancer,2019, 66(7):277-284.
[10] VERCELLINO L, DI BLASI R, KANOUN S, et al. Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma[J].Blood Adv,2020, 4(22):5607-5615.
[11] THURESSON P O, VANDER VELDE N, GUPTA P, et al.A systematic review of the clinical efficacy of treatments in relapsed or refractory diffuse large b cell lymphoma [J].Adv Ther,2020, 37(12):4877-4893.
[12] XU L, FENG J, TANG H, et al. Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib [J].Cell Death Dis,2020, 11(4):297-305.
[13] 杨理, 张炜, 张美兰, 等. 西达本胺联合R2-CHOP方案治疗复发难治EZB/C3亚型弥漫大B细胞淋巴瘤一例[J].中华血液学杂志, 2021, 42(5):436-437.
[14] ALBALAWI I A, MIR R, ABU DUHIER F M. Genetic effects of vascular endothelial growth factor A (VEGF-A) and its association with disease progression in breast cancer population of saudi arabia [J].Asian Pac J Cancer Prev,2020, 21(1):139-145.
[15] CHAI D, LI K, DU H, et al. β2-microglobulin has a different regulatory molecular mechanism between ER⁺ and ER^- breast cancer with HER2 [J].BMC Cancer,2019, 19(1):223-239.
[16] GUAN X W, WANG H Q, BAN W W, et al. Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20 [J].Cell Death Dis,2020, 11(1):20-26.